Clinical Trial Update: Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety, tolerability and mechanism of action of boswellic acids in relapsing remitting multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Boswellic acids (boswellic acids)

Snippet

Sponsor: Universitätsklinikum Hamburg-Eppendorf | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED